Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: CuttingEdge Bio who wrote (3332)	7/14/2021 10:12:45 PM
From: Felix B	Read Replies (1) \| Respond to of 3559

Perhaps a flop commercially but SNY was critical in funding REGN in the early days before it became profitable with Eylea. Sure, I wish Praulent, Kevzara and others would've worked out better financially but I don't think REGN would be where they are today without SNY.

To: CuttingEdge Bio who wrote (3332)	7/15/2021 7:17:32 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3559

< then the difference in profit sharing will not factor into that decision of which modality to pursue. > We are talking about cells surface receptors and its activation/deactivation (by Abs) ...not "deviated" messenger RNA that need to be corrected to (again) generate functional native protein. siRNA need to have target functions attached for uptake into specific deviant cells. Neurons, glia cells,...bits me will this ever work. For instance REGN chose to combine siRNA with its complement-Abs, and share profit...as it should be "differentiated" product that abs alone can not be. Sanofi screwed Praluent (legal issue with Amgen), it is not helping with Dupi, ...and BENEFITED 10X with its return on regn-investments. If J&J is "Sanofi" regn would be assimilated like Roche did with DNA! 800M investment in ALNY R&D, from where regn will consummate know-how and technology advantage in target validation, where siRNA can help a loot. I do not think there will be many product candidate at the end.